Bio-Key International Files 2023 Annual Report Amendment
Ticker: BKYI · Form: 10-K/A · Filed: Jun 20, 2024 · CIK: 1019034
Sentiment: neutral
Topics: amendment, annual-report, filing
TL;DR
BIO-KEY INTERNATIONAL INC filed a 10-K/A for FY2023 on 06/20/2024. Check for updates.
AI Summary
Bio-Key International, Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2023. The filing, dated June 20, 2024, provides updated information for the company, which is incorporated in Delaware and headquartered in Holmdel, NJ.
Why It Matters
This amendment to the annual report provides updated financial and operational information for Bio-Key International, Inc., which is crucial for investors and stakeholders to assess the company's performance and outlook.
Risk Assessment
Risk Level: low — This is a routine amendment to an annual report, not indicating new material adverse events.
Key Numbers
- 2023 — Fiscal Year End (The annual report covers the period ending December 31, 2023.)
- 10-K/A — Form Type (This filing is an amendment to the annual report.)
Key Players & Entities
- BIO KEY INTERNATIONAL INC (company) — Registrant
- December 31, 2023 (date) — Fiscal year end
- June 20, 2024 (date) — Filing date
- Delaware (location) — State of incorporation
- Holmdel, NJ (location) — Company headquarters
FAQ
What is the primary purpose of this 10-K/A filing?
This 10-K/A filing is an amendment to the annual report for the fiscal year ended December 31, 2023, providing updated information for Bio-Key International, Inc.
When was this amendment filed with the SEC?
This amendment was filed on June 20, 2024.
What is the fiscal year end date for the report being amended?
The fiscal year end date for the report being amended is December 31, 2023.
In which state is Bio-Key International, Inc. incorporated?
Bio-Key International, Inc. is incorporated in Delaware.
What is the company's principal business address?
The company's principal business address is 101 Crawfords Corner Road, Suite 4116, Holmdel, NJ 07753.
Filing Stats: 4,383 words · 18 min read · ~15 pages · Grade level 18.1 · Accepted 2024-06-20 17:20:24
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share BKYI Nasdaq Cap
- $13.50 — registrant's post-split common stock of $13.50 as reported by the Nasdaq Stock Market
- $729,905 — Swivel Secure, net of cash acquired of $729,905 - (623,578 ) Receipt of cash from
Filing Documents
- bkyi20231231_10ka.htm (10-K/A) — 1056KB
- ex_687768.htm (EX-31.1) — 9KB
- ex_687769.htm (EX-31.2) — 9KB
- ex_687770.htm (EX-32.1) — 6KB
- ex_687771.htm (EX-32.2) — 6KB
- 0001437749-24-020834.txt ( ) — 1377KB
- bkyi-20231231.xsd (EX-101.SCH) — 3KB
- bkyi-20231231_def.xml (EX-101.DEF) — 17KB
- bkyi-20231231_lab.xml (EX-101.LAB) — 23KB
- bkyi-20231231_pre.xml (EX-101.PRE) — 18KB
- bkyi20231231_10ka_htm.xml (XML) — 7KB
Financial Statements and Supplementary Data
Financial Statements and Supplementary Data 1 PART IV 31 Item 15 Exhibits and Financial Statement Schedules 31 Item 16 Form 10-K Summary
Signatures
Signatures 37 37
FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
FINANCIAL STATEMENTS
FINANCIAL STATEMENTS The following financial statements of BIO-key International, Inc. are included herein at the indicated page numbers: Report of Independent Registered Public Accounting Firm ( Bush and Associates CPA ., PCAOB ID: 6797 ) 2 Report of Independent Registered Public Accounting Firm (Marcum LLC., PCAOB ID:688) 3 Consolidated Balance Sheets as of December 31, 2023 and 2022 4 Consolidated Statements of Operations and Comprehensive Loss—Years ended December 31, 2023 and 2022 5 Consolidated Statements of Stockholders' Equity —Years ended December 31, 2023 and 2022 6 Consolidated Statements of Cash Flows—Years ended December 31, 2023 and 2022 7 Supplementary Disclosures of Cash Flow Information—Years ended December 31, 2023 and 2022 8 Notes to the Consolidated Financial Statements—December 31, 2023 and 2022 9 1 Table of Contents Report of Independent Registered Public Accounting Firm To the Shareholder and the Board of Directors of BIO-key International, Inc. Holmdel, NJ Opinion on the Financial Statements We have audited the retrospective adjustments related to the reverse stock split discussed in Note A, the accompanying consolidated balance sheet of BIO-key International, Inc. (the "Company") as of December 31, 2022. Additionally, we have audited the accompanying consolidated balance sheet of BIO-key International, Inc. and Subsidiaries (the "Company") as of December 31, 2023, and the related consolidated statements of operations and comprehensive loss, stockholders' equity and cash flows for the year then ended, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements and the retrospective adjustments related to the reverse stock split present fairly, in all material respects, the financial position of the Company as of December 31, 2023, and results of its operations and its cash flows for the year then ended in conformity with accounting principle